U.S. patent application number 09/963173 was filed with the patent office on 2002-03-28 for focused acoustic energy in the preparation of peptide arrays.
Invention is credited to Ellson, Richard N., Mutz, Mitchell W..
Application Number | 20020037359 09/963173 |
Document ID | / |
Family ID | 27100232 |
Filed Date | 2002-03-28 |
United States Patent
Application |
20020037359 |
Kind Code |
A1 |
Mutz, Mitchell W. ; et
al. |
March 28, 2002 |
Focused acoustic energy in the preparation of peptide arrays
Abstract
The present invention relates to arrays of peptidic molecules
and the preparation of peptide arrays using focused acoustic
energy. The arrays are prepared by acoustically ejecting
peptide-containing fluid droplets from individual reservoirs
towards designated sites on a substrate for attachment thereto.
Inventors: |
Mutz, Mitchell W.; (Palo
Alto, CA) ; Ellson, Richard N.; (Palo Alto,
CA) |
Correspondence
Address: |
REED & ASSOCIATES
800 MENLO AVENUE
SUITE 210
MENLO PARK
CA
94025
US
|
Family ID: |
27100232 |
Appl. No.: |
09/963173 |
Filed: |
September 25, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09963173 |
Sep 25, 2001 |
|
|
|
09669997 |
Sep 25, 2000 |
|
|
|
Current U.S.
Class: |
427/2.11 ;
435/176; 530/351; 530/388.1; 530/399 |
Current CPC
Class: |
B01J 2219/0061 20130101;
B01J 2219/00641 20130101; B01J 2219/00637 20130101; B01J 2219/00585
20130101; B01J 2219/00722 20130101; C40B 60/14 20130101; C40B 40/10
20130101; B01J 2219/0059 20130101; B01J 2219/00612 20130101; C40B
40/06 20130101; B01J 2219/00626 20130101; B01J 2219/0063 20130101;
B01J 2219/00527 20130101; B01J 2219/00725 20130101; B01J 2219/00659
20130101; B01J 2219/00497 20130101; B01J 19/0046 20130101; B01J
2219/00608 20130101; B01J 2219/00596 20130101; B01J 2219/00605
20130101; B05B 17/0615 20130101; B41J 2/14008 20130101; B01J
2219/00378 20130101 |
Class at
Publication: |
427/2.11 ;
530/351; 530/388.1; 530/399; 435/176 |
International
Class: |
B05D 003/00; C07K
014/52; C07K 016/00; A61K 038/24 |
Claims
We claim:
1. A method for preparing an array comprised of a plurality of
peptidic molecules attached to a substrate surface, the method
comprising applying focused acoustic energy to each of a plurality
of reservoirs each containing a peptidic molecule in a fluid,
wherein the focused acoustic energy is applied in a manner
effective to eject a droplet from each reservoir toward a different
site on a substrate surface.
2. The method of claim 1, wherein the focused acoustic energy is
applied to each of the plurality of reservoirs by (a) acoustically
coupling each reservoir in succession to an ejector that produces
acoustic radiation; and (b) following each acoustic coupling step,
activating the ejector to generate acoustic radiation having a
focal point sufficiently near the fluid surface so as to eject a
fluid droplet from the reservoir toward a designated site on the
substrate surface.
3. The method of claim 1, wherein each peptidic molecule is
comprised of about 5 to about 10,000 amino acids.
4. The method of claim 3, wherein each peptidic molecule is
comprised of about 5 to about 1,000 amino acids.
5. The method of claim 1, wherein each peptidic molecule is an
oligopeptide, a polypeptide or protein.
6. The method of claim 5, wherein the peptidic molecule is selected
from the group consisting of enzymes, antibodies, antigens,
coagulation modulators, cytokines, endorphins, peptidyl hormones
and kinins.
7. The method of claim 1, wherein each peptidic molecule is
different.
8. The method of claim 1, wherein each of the ejected droplets has
a volume in the range of about 1 pL to about 5 pL.
9. The method of claim 1, wherein each of the ejected droplets has
a volume of less than about 1 pL.
10. The method of claim 1, wherein the fluid has a viscosity of
least about 40 cP.
11. The method of claim 10, wherein the fluid has a viscosity of at
least about 100 cP.
12. The method of claim 11, wherein the fluid has a viscosity of at
least about 1000 cP.
13. A method for preparing a peptide array comprised of a plurality
of peptidic molecules attached to a substrate surface, the method
comprising: (a) acoustically coupling a first reservoir containing
a first peptidic molecule in a first fluid to an ejector that
produces acoustic radiation; (b) activating the ejector to generate
acoustic radiation having a focal point sufficiently near the
surface of the first fluid so as to eject a droplet thereof toward
a first designated site on the substrate surface; (c) acoustically
coupling a second reservoir containing a second peptidic molecule
in a second fluid to the ejector; (d) activating the ejector as in
step (b) to eject a droplet of the second fluid from the second
reservoir toward a second designated site on the substrate surface;
and (e) repeating steps (c) and (d) with additional reservoirs each
containing a peptidic molecule in a fluid until a droplet has been
ejected from each reservoir.
14. The method of claim 13, wherein the time period between
activation steps is no longer than about 1 second.
15. The method of claim 14, wherein the time period between
activation steps is no longer than about 0.1 second.
16. The method of claim 15, wherein the time period between
activation steps is no longer than about 0.01 second.
17. The method of claim 16, wherein the time period between
activation steps is no longer than about 0.001 second.
18. The method of claim 13, wherein steps (b) and (d) result in
attachment of the first and second peptidic molecules,
respectively, to the first and second designated sites on the
substrate surface.
19. The method of claim 18, wherein the attachment is covalent.
20. The method of claim 18, wherein the attachment is
noncovalent.
21. The method of claim 13, wherein each peptidic molecule is
comprised of about 5 to about 10,000 amino acids.
22. The method of claim 21, wherein each peptidic molecule is
comprised of about 5 to about 1,000 amino acids.
23. The method of claim 13, wherein each peptidic molecule is an
oligopeptide, a polypeptide or protein.
24. The method of claim 23, wherein the peptidic molecule is
selected from the group consisting of enzymes, antibodies,
antigens, coagulation modulators, cytokines, endorphins, peptidyl
hormones and kinins.
25. The method of claim 13, wherein each peptidic molecule is
different.
26. The method of claim 13, wherein each of the ejected droplets
has a volume in the range of about 1 pL to about 5 pL.
27. The method of claim 13, wherein each of the ejected droplets
has a volume of less than about 1 pL.
28. The method of claim 13, wherein each fluid has a viscosity of
least about 40 cP.
29. The method of claim 28, wherein the fluid has a viscosity of at
least about 100 cP.
30. The method of claim 29, wherein the fluid has a viscosity of at
least about 1000 cP.
31. The method of either claim 1 or claim 13, further comprising
pretreating the substrate surface with an activating agent.
32. The method of claim 31, wherein the activating agent is
cyanogen bromide, tresyl chloride or N-hydroxysuccinimide.
33. The method of either claim 1 or claim 13, wherein the substrate
surface is comprised of a porous material.
34. The method of claim 33, wherein the porous material is a
permeable material.
35. A method for preparing a peptide array comprised of a plurality
of peptidic molecules attached to a porous substrate surface, the
method comprising applying focused acoustic energy to each of a
plurality of fluid-containing reservoirs each containing a peptidic
molecule, wherein the focused acoustic energy is applied in a
manner effective to eject a droplet having a volume of at most
about 1 pL from each reservoir toward a different designated site
on the porous substrate surface.
36. The method of claim 35, wherein the array is prepared at a
density of at least about 1,000,000 peptidic molecules per square
centimeter of the substrate surface.
37. The method of claim 35, wherein the array is prepared at a
density of at least about 1,500,000 peptidic molecules per square
centimeter of the substrate surface.
38. A peptide array comprised of a plurality of peptidic molecules
each attached through an optional linking moiety to a substrate
surface, wherein substantially none of the peptidic molecules
exhibits signs of shear stress and substantially all of the
peptidic molecules are intact and attached to a predetermined site
on the substrate surface.
39. The peptide array of claim 38, wherein the attachment of the
peptidic molecules to the substrate surface is covalent.
40. The peptide array of claim 38, wherein the attachment of the
peptidic molecules to the substrate surface is noncovalent.
41. The peptide array of claim 38, wherein the peptidic molecules
are comprised of a plurality of peptidic molecule groups, wherein
(a) all peptidic molecules within any one group are different, and
(b) each peptidic molecule group is identical to each other
peptidic molecule group.
42. The peptide array of claim 38, wherein each peptidic molecule
is different.
43. The peptide array of claim 38, wherein each peptidic molecule
is comprised of about 5 to about 10,000 amino acids.
44. The peptide array of claim 43, wherein each peptidic molecule
is comprised of about 5 to about 1,000 amino acids.
45. The peptide array of claim 38, wherein each peptidic molecule
is an oligopeptide, a polypeptide or protein.
46. The peptide array of claim 45, wherein the peptidic molecule is
selected from the group consisting of enzymes, antibodies,
antigens, coagulation modulators, cytokines, endorphins, peptidyl
hormones and kinins.
47. The peptide array of claim 38, wherein the substrate surface is
comprised of a porous material.
48. The peptide array of claim 47, wherein the porous material is a
permeable material.
49. The peptide array of claim 38, wherein the peptidic molecules
are present in a density in the range of approximately 10 to
approximately 250,000 peptidic molecules per square centimeter of
substrate surface.
50. The peptide array of claim 38, wherein the peptidic molecules
are present in a density of at least about 1,000,000 peptidic
molecules per square centimeter of substrate surface.
51. The peptide array of claim 50, wherein the peptidic molecules
are present in a density of at least about 1,500,000 peptidic
molecules per square centimeter of substrate surface.
52. The peptide array of claim 38, wherein at least one designated
site on the substrate surface includes a lipidic material.
53. The peptide array of claim 52, wherein the lipidic material is
a phospholipid.
54. The peptide array of claim 52, wherein at least one of the
peptidic molecules within the array is in a lipidic material, and
at least one other of the peptidic molecules within the array is in
an aqueous fluid.
55. A peptide array comprised of a plurality of peptidic molecules
each attached through an optional linking moiety to a predetermined
site on a porous substrate surface at a density of greater than
1,000,000 peptidic molecules per square centimeter of the substrate
surface.
56. The peptide array of claim 55, wherein the density is greater
than 1,500,000 peptidic molecules per square centimeter of the
substrate surface.
57. The peptide array of claim 55, wherein the porous substrate
surface is a surface of a nonporous substrate.
58. The peptide array of claim 55, wherein the porous substrate
surface is a surface of a porous substrate.
59. The peptide array of claim 55, wherein the porous substrate
surface is a permeable surface.
60. The peptide array of claim 59, wherein the permeable surface is
a surface of a permeable substrate.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation-in-part of U.S. patent application
Ser. No. 09/669,997, filed Sep. 25, 2000, the disclosure of which
is incorporated by reference herein.
TECHNICAL FIELD
[0002] This invention relates generally to arrays of peptidic
molecules and methods for preparing peptide arrays. More
particularly, the invention pertains to the use of focused acoustic
ejection (FAE) technology in the preparation of peptide arrays.
BACKGROUND
[0003] The potential advantages of peptide arrays, i.e., arrays
composed of a plurality of peptidic molecules, are appreciated by
researchers, scientists and clinicians. Peptide arrays enable
high-throughput screening of compounds that may interact with one
or more peptides in the array in a particular manner. For example,
an array of peptidic molecules potentially suitable as ligands for
a particular biological receptor may be prepared and "screened"
with respect to that receptor. Also, arrays of antibodies may be
used to screen for multiple pathogenic antigens in a patient
sample. Combinations of proteins may also be used to screen for
molecules, which interact or are part of a similar metabolic
pathway. In addition, peptide arrays can be employed by clinicians
to determine whether or not a patient has developed antibodies to
particular peptidic antigens. The promise of peptidic arrays,
however, has been not been fully realized. This is in large part
due to manufacturing challenges, but other problems have been
encountered as well.
[0004] One proposed method for manufacturing peptide arrays
involves the use of piezoelectric technology, in particular, inkjet
printing technology. For example, U.S. Pat. No. 6,015,880 to
Baldeschwieler et al. is directed to array preparation and in situ
oligomer synthesis using a multistep process, wherein the oligomers
synthesized may be oligopeptides. A microdrop of a first reagent in
liquid form is applied through a single jet of a multiple jet
reagent dispenser to a locus on a surface chemically prepared to
react with and covalently attach the reagent. The multiple jet
reagent dispenser is then displaced relative to the surface, or the
surface is displaced with respect to the dispenser, and at least
one microdrop containing either the first reagent or a second
reagent from a different dispenser jet is applied to a second locus
on the substrate, which, again, is chemically prepared to react
with and covalently bind the second reagent. Optionally, the second
step is repeated using either the first or second reagents, or
different reagents in liquid form from different dispenser jets,
wherein the process results in an oligomer, such as an
oligopeptide, covalently attached to the substrate surface.
[0005] Ordinary inkjet technology, however, suffers from a number
of drawbacks. Often, inkjet technology involves heating or using a
piezoelectric element to force a fluid through a nozzle in order to
direct the ejected fluid onto a surface. Thus, the fluid may be
exposed to a surface exceeding 200.degree. C. before being ejected,
and most, if not all, peptidic molecules, including proteins,
degrade under such extreme temperatures. In addition, forcing
peptidic molecules through nozzles creates shear forces that can
alter molecular structure. Nozzles are subject to clogging,
especially when used to eject a macromolecule-containing fluid, and
the use of elevated temperatures exacerbates the problem because
liquid evaporation results in deposition of precipitated solids on
the nozzles. Clogged nozzles, in turn, can result in misdirected
fluid or ejection of improperly sized droplets. Finally, ordinary
inkjet technology employing a nozzle for fluid ejection generally
cannot be used to deposit arrays with feature densities comparable
to those obtainable using photolithography or other techniques
commonly used in semiconductor processing.
[0006] Photolithographic techniques have also been proposed for use
in the manufacture peptidic arrays. For example, U.S. Pat. Nos.
5,143,854 and 5,405,783 to Pirrung et al., and U.S. Pat. Nos.
5,445,934 and 5,744,305 to Fodor et al. describe solid phase
synthesis of oligomers, including peptidic oligomers, employing
photolithographic techniques. These techniques, however, require a
large number of masking steps, resulting in a relatively low
overall yield, and are prohibitively expensive. In addition,
photolithographic techniques often leave behind small amounts of
photolithographic processing materials, e.g., photolabile groups.
Furthermore, the purity of the peptidic molecules within the array
is relatively low, given that truncated proteins result from missed
steps (e.g., failure of a photolabile group to be removed), and
imprecise masking placement results in misplaced material.
[0007] Both approaches inkjet and photolithographic processes
generally rely on in situ preparation of the peptidic molecules.
These techniques are generally unsuitable for producing high
density arrays of even moderately sized peptidic molecules. For
example, in situ synthesis of peptides using photolithographic
techniques could require over 100 masks for a peptide only six
amino acids in length. Furthermore, there is no guarantee that
proteins synthesized in situ will adopt the secondary and tertiary
structure necessary for biological activity.
[0008] A number of patents have described the use of acoustic
energy in printing. For example, U.S. Pat. No. 4,308,547 to
Lovelady et al. describes a liquid drop emitter that utilizes
acoustic principles in ejecting droplets from a body of liquid onto
a moving document to form characters or bar codes thereon. A
nozzleless inkjet printing apparatus is used wherein controlled
drops of ink are propelled by an acoustical force produced by a
curved transducer at or below the surface of the ink. In contrast
to inkjet printing devices, nozzleless fluid ejection devices
described in the aforementioned patent are not subject to clogging
and the disadvantages associated therewith, e.g., misdirected fluid
or improperly sized droplets.
[0009] The applicability of nozzleless fluid ejection has generally
been appreciated for ink printing applications. Development of ink
printing applications is primarily economically driven by printing
cost and speed for acceptable text. For acoustic printing,
development efforts have therefore focused on reducing printing
costs rather than improving quality, and on increasing printing
speed rather than accuracy. For example, U.S. Pat. No. 5,087,931 to
Rawson is directed to a system for transporting ink under constant
flow to an acoustic ink printer having a plurality of ejectors
aligned along an axis, each ejector associated with a free surface
of liquid ink. When a plurality of ejectors is used instead of a
single ejector, printing speed generally increases, but controlling
fluid ejection, specifically droplet placement, becomes more
difficult.
[0010] U.S. Pat. No. 4,797,693 to Quate describes an acoustic ink
printer for printing polychromatic images on a recording medium.
The printer is described as comprising a combination of a carrier
containing a plurality of differently colored liquid inks, a single
acoustic printhead acoustically coupled to the carrier for
launching converging acoustic waves into the carrier, an ink
transport means to position the carrier to sequentially align the
differently colored inks with the printhead, and a controller to
modulate the radiation pressure used to eject ink droplets. This
printer is described as designed for the realization of cost
savings. Because two droplets of primary color, e.g., cyan and
yellow, deposited in sufficient proximity will appear as a
composite or secondary color, the level of accuracy required is
fairly low and inadequate for biomolecular array formation. Such a
printer is particularly unsuitable for in situ synthesis requiring
precise droplet deposition and consistent placement, so that the
proper chemical reactions occur. That is, the drop placement
accuracy needed to effect perception of a composite secondary color
is much lower than is required for chemical synthesis at
photolithographic density levels. Consequently, an acoustic
printing device that is suitable for printing visually
apprehensible material is inadequate for microarray preparation.
Also, this device can eject only a limited quantity of ink from the
carrier before the liquid meniscus moves out of acoustic focus and
drop ejection ceases. This is a significant limitation with
biological fluids, which are typically far more costly and rare
than ink. The Quate et al. patent does not address how to use most
of the fluid in a closed reservoir without adding additional liquid
from an external source.
[0011] Thus, there is a need in the art for improved acoustic fluid
ejection methods having sufficient droplet ejection accuracy so as
to enable the preparation of high density peptidic arrays without
the disadvantages associated with photolithographic techniques or
inkjet printing devices relying on a nozzle or relatively large
volumes of materials for droplet ejection. Specifically, acoustic
fluid ejection devices as described herein provide improved control
over the spatial direction of fluid ejection without the
disadvantages of lack of flexibility and uniformity associated with
photolithographic techniques or inkjet printing devices.
SUMMARY OF THE INVENTION
[0012] Accordingly, it is an object of the present invention to
provide a method for preparing a peptide array that is not subject
to the above-mentioned disadvantages of the prior art.
[0013] It is another object of the invention to provide a method
for preparing a peptide array by applying focused acoustic energy
to fluid-containing reservoirs, wherein each reservoir contains a
peptidic molecule.
[0014] It is still another object of the invention to provide a
method for preparing peptide arrays wherein the method is minimally
or completely unaffected by the use of relatively viscous fluids
containing peptidic molecules.
[0015] It is yet another object of the invention to provide a
method for preparing peptide arrays wherein the method does not
result in or minimizes the exposure of peptidic molecules to shear
stress or high temperature.
[0016] It is a further object of the invention to provide peptide
arrays prepared using the aforementioned method.
[0017] It is another object of the invention to provide peptide
arrays wherein substantially none of the peptidic molecules
exhibits signs of shear stress and all peptidic molecules are
"pure," i.e., intact and identical to the peptidic molecules in the
fluids from which they are ejected.
[0018] It is still another object of the invention to provide
peptide arrays wherein substantially none of the peptidic molecules
exhibits signs of shear stress and at least one designated site on
the substrate surface includes a lipidic material.
[0019] Additional objects, advantages and novel features of the
invention will be set forth in part in the description which
follows, and in part will become apparent to those skilled in the
art upon examination of the following, or may be learned by
practice of the invention.
[0020] In one aspect of the invention, a method is provided for
preparing a peptide array comprised of a plurality of peptidic
molecules each attached to a designated site on a substrate
surface. The method comprises applying focused acoustic energy to
each of a plurality of fluid-containing reservoirs containing a
peptidic molecule to be applied to a particular site on the
substrate surface and attached thereto. It is preferred that the
focused acoustic energy is applied to each of the plurality of
fluid-containing reservoirs by acoustically coupling each reservoir
in succession to a single ejector that produces acoustic radiation.
Following each acoustic coupling step, the ejector is activated to
generate acoustic radiation having a focal point within the
reservoir fluid and sufficiently near the surface thereof such that
a droplet of fluid is ejected from the reservoir toward a
particular site on the substrate surface.
[0021] In another aspect of the invention, a peptide array is
provided comprised of a plurality of peptidic molecules attached to
a substrate surface through an optional linking moiety.
Substantially none of the peptidic molecules of the peptide array
exhibits signs of shear stress. Further, substantially all of the
peptide molecules are intact and attached to a predetermined site
on the substrate surface, and/or at least one designated site on
the substrate surface includes a lipidic material. In addition, the
peptide array is preferably substantially free of photolithographic
processing materials.
[0022] The present focused acoustic ejection methodology enables
preparation of high-density peptidic arrays comprised of at least
62,500 peptidic molecules (i.e., array elements) per square
centimeter of substrate surface, preferably at least 250,000, more
preferably at least 1,000,000, and most preferably at least
1,500,000 peptidic molecules per square centimeter of substrate
surface.
[0023] Although any mode of attachment may be used, covalent
attachment of the peptidic molecules to the substrate surface is
preferred in most instances. Alternatively, attachment of the
peptidic molecules to the substrate surface may be noncovalent; for
example, the peptidic molecules can be adsorbed onto the substrate
surface or physically immobilized thereon. The substrate surface
can be comprised of any suitable material that allows for
attachment of peptidic molecules; however, substrate surfaces
comprised of a porous material are preferred.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIGS. 1 and 2 schematically illustrate in simplified
cross-sectional view an embodiment of a device useful in
conjunction with the method of the invention, the device comprising
first and second reservoirs, an acoustic ejector, and an ejector
positioning means. FIG. 1 shows the acoustic ejector acoustically
coupled to the first reservoir and having been activated in order
to eject a droplet of fluid from within the first reservoir toward
a designated site on a substrate surface. FIG. 2 shows the acoustic
ejector acoustically coupled to a second reservoir.
DETAILED DESCRIPTION OF THE INVENTION
[0025] Before describing the present invention in detail, it is to
be understood that this invention is not limited to specific
fluids, peptidic molecules or device structures, as such may vary.
It is also to be understood that the terminology used herein is for
the purpose of describing particular embodiments only, and is not
intended to be limiting.
[0026] It must be noted that, as used in this specification and the
appended claims, the singular forms "a," "an" and "the" include
plural referents unless the context clearly dictates otherwise.
Thus, for example, reference to "a reservoir" includes not only a
single reservoir but also a plurality of reservoirs, reference to
"a peptidic molecule" includes a single peptidic molecule as well
as a combination of different peptidic molecules, and the like.
[0027] In describing and claiming the present invention, the
following terminology will be used in accordance with the
definitions set out below.
[0028] The terms "acoustic coupling" and "acoustically coupled"
used herein refer to a state wherein a first entity is placed in
direct or indirect contact with another entity so as to allow
acoustic radiation to be transferred between the objects without
substantial loss of acoustic energy. When two entities are
indirectly acoustically coupled, an "acoustic coupling medium" is
needed to provide an intermediary through which acoustic radiation
may be transmitted. Thus, an ejector may be acoustically coupled to
a fluid, e.g., by immersing the ejector in the fluid or by
interposing an acoustic coupling medium between the ejector and the
fluid to transfer acoustic radiation generated by the ejector
through the acoustic coupling medium and into the fluid.
[0029] The term "adsorb" as used herein refers to the noncovalent
retention of a molecule by a substrate surface. That is, adsorption
occurs as a result of noncovalent interaction between a substrate
surface and adsorbing moieties present on the molecule that is
adsorbed. Adsorption may occur through hydrogen bonding, van der
Waal's forces, polar attraction or electrostatic forces (i.e.,
through ionic bonding). Examples of adsorbing moieties include, but
are not limited to, amine groups, carboxylic acid moieties,
antibodies, hydroxyl groups, nitroso groups, sulfones and the like.
Often the substrate may be functionalized with adsorbent moieties
to interact in a certain manner, as when the surface is
functionalized with amino groups to render it positively charged in
a pH neutral aqueous environment. Likewise, adsorbate moieties may
be added in some cases to effect adsorption, as when a basic
protein is fused with an acidic peptide sequence to create
adsorbate moieties that can interact electrostatically with a
positively charged adsorbent moiety.
[0030] The term "array" as used herein refers to a two-dimensional
arrangement of features on a substrate surface. In the present
arrays, the "features" are peptidic molecules. Arrays are generally
comprised of regular, ordered features, as in, for example, a
rectilinear grid, parallel stripes, spirals, and the like, but
non-ordered arrays may be advantageously used as well. The arrays
prepared using the method of the invention generally comprise in
the range of about 4 to about 10,000,000 features, more typically
about 4 to about 1,000,000 features.
[0031] The term "attached," as in, for example, a substrate surface
having a peptidic molecule "attached" thereto, includes covalent
binding, adsorption, and physical immobilization. The terms
"binding" and "bound" are identical in meaning to the term
"attached."
[0032] The term "peptidic molecule" as used throughout the
specification and claims is intended to include any structure
comprised of one or more amino acids. Generally, since the peptidic
molecules are typically pre-formed and spotted onto the substrate
as intact molecules, they are comprised of two or more amino acids,
and are peptides, polypeptides or proteins. Normally, amino acids
will serve as the peptidic molecules only when the peptide array is
prepared via stepwise in situ synthesis on the solid support. For
the most part, then, the peptidic molecules in the present arrays
comprise about 5 to 10,000 amino acids, preferably about 5 to 1000
amino acids. The amino acids forming all or a part of a peptidic
molecule may be any of the twenty conventional, naturally occurring
amino acids, i.e., alanine (A), cysteine (C), aspartic acid (D),
glutamic acid (E), phenylalanine (F), glycine (G), histidine (H),
isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine
(N), proline (P), glutamine (Q), arginine (R), serine (S),
threonine (T), valine (V), tryptophan (W), and tyrosine (Y). Any of
the amino acids in the peptidic molecules forming the present
arrays may be replaced by a non-conventional amino acid. In
general, conservative replacements are preferred. Conservative
replacements substitute the original amino acid with a
non-conventional amino acid that resembles the original in one or
more of its characteristic properties (e.g., charge,
hydrophobicity, stearic bulk; for example, one may replace Val with
Nval). The term "non-conventional amino acid" refers to amino acids
other than conventional amino acids, and include, for example,
isomers and modifications of the conventional amino acids, e.g.,
D-amino acids, non-protein amino acids, post-translationally
modified amino acids, enzymatically modified amino acids,
constructs or structures designed to mimic amino acids (e.g.,
.alpha.,.alpha.-disubstituted amino acids, N-alkyl amino acids,
lactic acid, .beta.-alanine, naphthylalanine, 3-pyridylalanine,
4-hydroxyproline, O-phosphoserine, N-acetylserine,
N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and
nor-leucine), and other non-conventional amino acids, as described,
for example, in U.S. Pat. No. 5,679,782 to Rosenberg et al. The
peptidic molecules may also contain nonpeptidic backbone linkages,
wherein the naturally occurring amide --CONH-- linkage is replaced
at one or more sites within the peptide backbone with a
non-conventional linkage such as substituted amide, ester,
thioamide, retropeptide (--NHCO--), retrothioamide (--NHCS--),
sulfonamido (--SO.sub.2NH--), and/or peptoid (N-substituted
glycine) linkages. Accordingly, the peptidic molecules of the array
include pseudopeptides and peptidomimetics. The peptides of this
invention can be (a) naturally occurring, (b) produced by chemical
synthesis, (c) produced by recombinant DNA technology, (d) produced
by biochemical or enzymatic fragmentation of larger molecules, (e)
produced by methods resulting from a combination of methods (a)
through (d) listed above, or (f) produced by any other means for
producing peptides.
[0033] As will be appreciated by those skilled in the art, peptidic
molecules have certain levels of structure. The primary structure
of a peptidic molecule is generally the amino acid sequence per se,
while the secondary structure of a peptidic molecule refers to the
regular, local structures of linear segments of polypeptide chains,
such as a helix, an extended strand, or a .beta.-pleated sheet. The
tertiary structure of a peptide refers to the overall topology of
the molecule, resulting from, for example, folding within a
polypeptide chain. See Creighton, Proteins: Structures and
Molecular Properties, 2.sup.nd Edition (W. H. Freeman and Company,
New York, 1993). Although each structural level is critical for the
properties and biological activity of a peptidic molecule, the
secondary and tertiary structures are particularly sensitive to
shearing forces. When exposed to shear, a peptidic molecule's
secondary and/or tertiary structure can be irreversibly altered,
potentially resulting in loss of biological activity. Of course,
the primary structure, i.e., the amino acid sequence, may be
destroyed or interrupted if the peptidic molecule is subjected to
sufficient shear force.
[0034] The term "fluid" as used herein refers to matter that is
nonsolid or at least partially gaseous and/or liquid. A fluid may
contain a solid that is minimally, partially or fully solvated,
dispersed or suspended. Examples of fluids include, without
limitation, aqueous liquids (including water per se and buffered
water), nonaqueous liquids such as organic solvents and lipidic
liquids, supercritical fluids, gases, and the like. As used herein,
the term "fluid" is not synonymous with the term "ink" in that an
ink must contain a colorant and may not be gaseous.
[0035] The term "near" is used to refer to the distance from the
focal point of the focused acoustic radiation to the surface of the
fluid from which a droplet is to be ejected. The distance should be
such that the focused acoustic radiation directed into the fluid
results in droplet ejection from the fluid surface, and one of
ordinary skill in the art will be able to select an appropriate
distance for any given fluid using straightforward and routine
experimentation. Generally, however, a suitable distance between
the focal point of the acoustic radiation and the fluid surface is
in the range of about 1 to about 15 times the wavelength of the
speed of sound in the fluid, more typically in the range of about 1
to about 10 times that wavelength, preferably in the range of about
1 to about 5 times that wavelength.
[0036] The terms "focusing means" and "acoustic focusing means"
refer to a means for causing acoustic waves to converge at a focal
point by either a device separate from the acoustic energy source
that acts like an optical lens, or by the spatial arrangement of
acoustic energy sources to effect convergence of acoustic energy at
a focal point by constructive and destructive interference. A
focusing means may be as simple as a solid member having a curved
surface, or it may include complex structures such as those found
in Fresnel lenses, which employ diffraction in order to direct
acoustic radiation. Suitable focusing means also include phased
array methods as known in the art and described, for example, in
U.S. Pat. No. 5,798,779 to Nakayasu et al. and Amemiya et al.
(1997) Proceedings of the 1997 IS&T NIP13 International
Conference on Digital Printing Technologies Proceedings, at pp.
698-702.
[0037] The term "reservoir" as used herein refers to a receptacle
or chamber for holding or containing a fluid. Thus, a fluid in a
reservoir necessarily has a free surface, i.e., a surface that
allows a droplet to be ejected therefrom. A reservoir may also be a
locus on a substrate surface within which a fluid is
constrained.
[0038] The term "substrate" as used herein refers to any material
having a surface onto which one or more fluids may be deposited.
The substrate may be constructed in any of a number of forms such
as wafers, slides, well plates, membranes, for example. In
addition, the substrate may be porous or nonporous as may be
required for deposition of a particular fluid. Suitable substrate
materials include, but are not limited to, supports that are
typically used for solid phase chemical synthesis, e.g., polymeric
materials (e.g., polystyrene, polyvinyl acetate, polyvinyl
chloride, polyvinyl pyrrolidone, polyacrylonitrile, polyacrylamide,
polymethyl methacrylate, polytetrafluoroethylene, polyethylene,
polypropylene, polyvinylidene fluoride, polycarbonate,
divinylbenzene styrene-based polymers), agarose (e.g.,
Sepharose.RTM.), dextran (e.g., Sephadex.RTM.), cellulosic polymers
and other polysaccharides, silica and silica-based materials, glass
(particularly controlled pore glass, or "CPG") and functionalized
glasses, ceramics, and such substrates treated with surface
coatings, e.g., with microporous polymers (particularly cellulosic
polymers such as nitrocellulose), microporous metallic compounds
(particularly microporous aluminum), antibody-binding proteins
(available from Pierce Chemical Co., Rockford Ill.), bisphenol A
polycarbonate, or the like.
[0039] Substrates of particular interest are porous, and include,
as alluded to above: uncoated porous glass slides, including CPG
slides; porous glass slides coated with a polymeric coating, e.g.,
an aminosilane or poly-L-lysine coating, thus having a porous
polymeric surface; and nonporous glass slides coated with a porous
coating. The porous coating may be a porous polymer coating, such
as may be comprised of a cellulosic polymer (e.g., nitrocellulose)
or polyacrylamide, or a porous metallic coating (for example,
comprised of microporous aluminum). Examples of commercially
available substrates having porous surfaces include the Fluorescent
Array Surface Technology (FAST.TM.) slides available from
Schleicher & Schuell, Inc. (Keene, N.H.), which are coated with
a 10-30 .mu.m thick porous, fluid-permeable nitrocellulose layer
that substantially increases the available binding area per unit
area of surface. Other commercially available porous substrates
include the CREATIVECHIP.RTM. permeable slides currently available
from Eppendorf AG (Hamburg, Germany), and substrates having
"three-dimensional" geometry, by virtue of an ordered, highly
porous structure that enables reagents to flow into and penetrate
through the pores and channels of the entire structure. Such
substrates are available from Gene Logic, Inc. under the tradename
"Flow-Thru Chip," and are described by Steel et al. in Chapter 5 of
Microarray Biochip Technology (BioTechniques Books, Natick, Mass.,
2000).
[0040] The term "porous" as in a "porous substrate" or a "substrate
having a porous surface," refers to a substrate or surface,
respectively, having a porosity (void percentage) in the range of
about 1% to about 99%, preferably about 5% to about 99%, more
preferably in the range of about 15% to about 95%, and an average
pore size of about 100 .ANG. to about 1 mm, typically about 500
.ANG. to about 0.5 mm.
[0041] The term "impermeable" is used in the conventional sense to
mean not permitting water or other fluid to pass through. The term
"permeable" as used herein means not "impermeable." Thus, a
"permeable substrate" and a "substrate having a permeable surface"
refer to a substrate or surface, respectively, which can be
permeated with water or other fluid.
[0042] While the foregoing support materials are representative of
conventionally used substrates, it is to be understood that a
substrate may in fact comprise any biological, nonbiological,
organic and/or inorganic material, and may be in any of a variety
of physical forms, e.g., particles, strands, precipitates, gels,
sheets, tubing, spheres, containers, capillaries, pads, slices,
films, plates, and the like, and may further have any desired
shape, such as a disc, square, sphere, circle, etc. The substrate
surface may or may not be flat, e.g., the surface may contain
raised or depressed regions. A substrate may additionally contain
or be derivatized to contain reactive functionalities that
covalently link a compound to the substrate surface. These are
widely known and include, for example, silicon dioxide supports
containing reactive Si--OH groups, polyacrylamide supports,
polystyrene supports, polyethylene glycol supports, and the
like.
[0043] The term "surface modification" as used herein refers to the
chemical and/or physical alteration of a surface by an additive or
subtractive process to change one or more chemical and/or physical
properties of a substrate surface or a selected site or region of a
substrate surface. For example, surface modification may involve
(1) changing the wetting properties of a surface, (2)
functionalizing a surface, i.e., providing, modifying or
substituting surface functional groups, (3) defunctionalizing a
surface, i.e., removing surface functional groups, (4) otherwise
altering the chemical composition of a surface, e.g., through
etching, (5) increasing or decreasing surface roughness, (6)
providing a coating on a surface, e.g., a coating that exhibits
wetting properties that are different from the wetting properties
of the surface, and/or (7) depositing particulates on a surface.
Also included are those surface modifications that help preserve
the structure (e.g., tertiary structure) of a protein by, for
example, surface application of a lipidic material such as a
phospholipid.
[0044] "Optional" or "optionally" means that the subsequently
described circumstance may or may not occur, so that the
description includes instances where the circumstance occurs and
instances where it does not.
[0045] The term "substantially" as in, for example, the phrase
"substantially all molecules of an array," refers to at least 90%,
preferably at least 95%, more preferably at least 99%, and most
preferably at least 99.9%, of the molecules of an array. Other uses
of the term "substantially" involve an analogous definition.
[0046] In one embodiment, the invention pertains to a method for
preparing a peptide array on a substrate surface, the method
comprising applying focused acoustic energy to each of a plurality
of fluid-containing reservoirs wherein each of the reservoirs
contains a peptidic molecule in a fluid to be applied to a
designated site on the substrate surface and attached thereto. The
acoustic ejection device used to effect droplet ejection includes
(a) an ejector comprised of an acoustic radiation generator for
generating acoustic radiation and a focusing means for focusing
acoustic radiation at a focal point within and near the fluid
surface in each of the reservoirs, and (b) a means for positioning
the ejector in acoustic coupling relationship to each of the
reservoirs. Preferably, the device is coupled to each of the
plurality of fluid-containing reservoirs in succession and
activated to eject a droplet from each reservoir.
[0047] Initially, a first fluid-containing reservoir containing a
first peptidic molecule is acoustically coupled to the acoustic
ejector. Thereafter, the ejector is activated to generate acoustic
radiation having a focal point sufficiently near the surface of the
reservoir fluid so as to result in ejection of a fluid droplet from
the reservoir toward a designated site on the substrate surface.
Next, a second fluid-containing reservoir containing a second
peptidic molecule is acoustically coupled to the ejector. Again,
the ejector is activated to eject a droplet of fluid from the
second reservoir toward a second designated site on the substrate
surface. The process is repeated until a droplet has been ejected
from each of the plurality of reservoirs. Typically, the droplets
each have a volume of about 1 picoliter or less (e.g., 0.02 to 1
pL), enabling spotting at very high densities. In some cases, of
course, spotting droplets of substantially greater volume may be
desirable.
[0048] Once ejected, each peptidic molecule attaches to a
particular location on the substrate surface. Attachment may be
covalent or noncovalent, e.g., via ionic bonding, hydrogen bonding,
adsorption or physical immobilization, and may or may not involve a
linker between the peptidic molecule and the substrate surface. For
example, the carboxyl terminus of a peptide may bind to a free
amino group on an amine-derivatized substrate surface, resulting in
an amide linkage. Conversely, primary amine groups in the peptidic
moiety may be attached covalently to a surface via a succinimidyl
ester group. As another example, an antibody (available
commercially or using standard techniques of antibody production)
may be bound to a peptidic molecule to provide a linker that can
attach to a substrate surface functionalized with an
antibody-binding protein, e.g., protein A that binds to the Fc
portion of IgG and/or IgM antibodies, or protein L that binds to
all classes of antibodies, e.g., immunoglobulins that contain kappa
light chains. Biotin-streptavidin attachments are also
contemplated.
[0049] A linker, if present, should have a length sufficient to
allow another molecular entity (e.g., a potential ligand) to bind
to the peptidic molecule. The linker may contain a cleavable site
to allow release of the peptidic molecule from the substrate
surface after use, e.g., after completion of a binding or screening
assay. Selectably cleavable sites may be enzymatically, chemically,
thermally or photolytically cleavable, as described in U.S. Pat.
Nos. 4,775,619, 5,118,605, 5,258,506, 5,367,066, 5,380,833,
5,580,731 and 5,591,584. As explained in the aforementioned
patents, a number of reagents and methods may be used to create
sites that are cleavable using chemical reagents, restriction
enzymes or photolysis.
[0050] As will be appreciated by those in the art, some substrate
surfaces may require activation treatment in order to facilitate
coupling of the peptidic molecule. Any art-known treatment may be
employed. Examples of preferred treatment methods for activating
substrate surfaces include treatment with an activating agent such
as cyanogen bromide, tresyl chloride or N-hydroxysuccinimide. Other
methods for activating substrate surfaces may also be employed.
[0051] As will be recognized by those skilled in the art, fluids
that contain peptidic molecules may be somewhat viscous.
Advantageously, the present method neither requires nozzles nor
includes parts that may become clogged with relatively viscous
fluids. Thus, the invention enables acoustical ejection of a
plurality of fluids, wherein at least one fluid has a viscosity of
least about 40 centipoise (cP). In addition, the method remains
effective even when at least one of the fluids has a viscosity as
high as 100 cP, and even 1000 cP (absolute viscosity).
[0052] It is preferred that the three-dimensional structure, i.e.,
the secondary and tertiary structure, of the peptidic molecule is
preserved in the fluid. Preferred fluids for preserving peptidic
structure comprise a solvent and a reagent capable of maintaining
the pH. Additional components, such as a stabilizer (e.g., bovine
serum albumin), may also be present in the fluid, if necessary.
Suitable solvents for protein-containing fluids are well known in
the art and typically comprise water as a solvent and an acid-base
conjugate pair to maintain pH. Organic solvents may also be
employed. Suitable reagents capable of maintaining pH include, for
example, N-2-acetamido-2-aminoethanesulfonic acid (ACES), ammonium
acetate, N,N-bis-(2-hydroxyethyl)-glycine,
N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES),
[bis]-(2-hydroxyethyl)imino]-tris-(hydroxymethyl)-methane
(BIS-Tris), 1,3-bis-[tris-(hydroxymethyl)methylamino]-propane
(BIS-Tris-propane), 3-(cyclohexylamino)-propane-sulfonic acid
(CAPS), 2-(N-cyclohexylamino)et- hane-sulfonic acid) (CHES),
glycine, glycine amide, 2-(N-morpholino)ethanesulfonic acid (MES),
3-(N-morpholino)ethanesulfonic acid (MOPS),
piperazine-N,N'-bis-)2-ethane-sulfonic acid (PIPES),
(N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) (HEPES),
3-{[tris-(hydroxymethyl)-methyl]amino}-propanesulfonic acid (TAPS),
2-{[tris-(hydroxymethyl)-methyl]-amino}-ethanesulfonic acid (TES),
N-{tris-(hydroxy-methyl-methyl]-glycine} (Tricine),
triethanolamine, tris-(hydroxymethyl)-aminomethane (TRIS), boric
acid, cacodylic acid, potassium phosphate, sodium acetate, sodium
citrate, sodium phosphate and combinations thereof. Solutions of a
solvent and/or stabilizer can also be employed as part of a
pre-treatment of the surface or applied after deposition of the
peptidic molecule in order to preserve the structure of the
peptidic molecule.
[0053] In another embodiment, a peptide array is provided that is
comprised of a plurality of peptidic molecules each attached
through an optional linking moiety to a substrate surface, wherein
substantially none of the peptidic molecules exhibits signs of
shear stress and substantially all of the peptidic molecules are
pure, i.e., intact, and attached to a predetermined site on the
substrate surface. In an alternative embodiment, a peptide array is
provided that is comprised of a plurality of peptidic molecules
each attached through an optional linking moiety to a substrate
surface, wherein substantially none of the peptidic molecules
exhibits signs of shear stress and at least one designated site on
the substrate includes a lipidic material. The peptidic array may
be a combinatorial library of peptidic molecules, i.e., an array
wherein each peptidic molecule is different from every other
peptidic molecule.
[0054] Peptidic compounds include any pharmacologically active
peptide, polypeptide or protein, such as, but not limited to
enzymes, monoclonal and polyclonal antibodies, antigens,
coagulation modulators, cytokines, endorphins, peptidyl hormones,
kinins, and structurally similar bioactive equivalents thereof. By
a "structurally similar bioactive equivalent" is meant a peptidyl
compound with structure sufficiently similar to that of an
identified bioactive peptidyl compound to produce substantially
equivalent therapeutic effects. As used herein and in the appended
claims, the terms "protein", "peptide" and "polypeptide" refer to
both the specific peptidic compound(s) identified as well as
structurally similar bioactive equivalents thereof.
[0055] Examples of various peptidyl compounds are as follows:
[0056] Coagulation modulators include .alpha..sub.1-antitrypsin,
.alpha..sub.2-macroglobulin, antithrombin III, factor I
(fibrinogen), factor II (prothrombin), factor III (tissue
prothrombin), factor V (proaccelerin), factor VII (proconvertin),
factor VIII (antihemophilic globulin or AHG), factor IX (Christmas
factor, plasma thromboplastin component or PTC), factor X
(Stuart-Power factor), factor XI (plasma thromboplastin antecedent
or PTA), factor XII (Hageman factor), heparin cofactor II,
kallikrein, plasmin, plasminogen, prekallikrein, protein C, protein
S, thrombomodulin and combinations thereof.
[0057] Cytokines include, but are not limited to, the following:
transforming growth factors (TGFs) such as TGF-.beta.1,
TGF-.beta.2, and TGF-.beta.3; bone morphogenetic proteins (for
example, BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8,
BMP-9); heparin-binding growth factors (for example, fibroblast
growth factor (FGF), epidermal growth factor (EGF),
platelet-derived growth factor (PDGF), heparin-binding neurotrophic
factor (HBNF), and insulin-like growth factor (IGF)); connective
tissue activated peptides (CTAPs), osteogenic factors; colony
stimulating factor; interferons, including interferon-.alpha.,
interferon .alpha.-2a, interferon .alpha.-2b, interferon
.alpha.-n3, interferon-.beta., and interferon-.gamma.;
interleukins, including interleukin-1, interleukin-2,
interleukin-3, interleukin-4, interleukin-5, interleukin-6,
interleukin-7, interleukin-8, interleukin-9, interleukin-10,
interleukin-11, interleukin-12, interleukin-13, interleukin-14,
interleukin-15, interleukin-16, and interleukin-17; tumor necrosis
factor; tumor necrosis factor-.alpha.; granuloycte
colony-stimulating factor (G-CSF); granulocyte-macrophage
colony-stimulating factor (GM-CSF); macrophage colony-stimulating
factor; Inhibins (e.g., Inhibin A and Inhibin B); growth
differentiating factors (e.g., GDF-1); Activins (e.g., Activin A,
Activin B, and Activin AB); midkine (MD); and thymopoietin.
[0058] Endorphins are peptides that activate opiate receptors.
Agonist and antagonist derivatives of the naturally occurring
endorphins are also contemplated. Representative examples of
endorphins and pharmacologically active endorphin derivatives
include dermorphin, dynorphin, .alpha.-endorphin, .beta.-endorphin,
.gamma.-endorphin, .sigma.-endorphin [Leu.sup.5]enkephalin,
[Met.sup.5]enkephalin, substance P, and combinations thereof.
[0059] Peptidyl hormones include, but are not limited to, activin,
amylin, angiotensin, atrial natriuretic peptide (ANP), calcitonin
(derived from chicken, eel, human, pig, rat, salmon, etc.),
calcitonin gene-related peptide, calcitonin N-terminal flanking
peptide, cholecystokinin (CCK), ciliary neurotrophic factor (CNTF),
corticotropin (adrenocorticotropin hormone, ACTH),
corticotropin-releasing factor (CRF or CRH), follicle-stimulating
hormone (FSH), gastrin, gastrin inhibitory peptide (GIP),
gastrin-releasing peptide, glucagon, gonadotropin-releasing factor
(GnRF or GNRH), growth hormone releasing factor (GRF, GRH), human
chorionic gonadotropin (hCH), inhibin A, inhibin B, insulin
(derived from beef, human, pig, etc.), leptin, lipotropin (LPH),
luteinizing hormone (LH), luteinizing hormone-releasing hormone
(LHRH), lypressin, .alpha.-melanocyte-stimulating hormone,
.beta.-melanocyte-stimulating hormone,
.gamma.-melanocyte-stimulating hormone, melatonin, motilin,
oxytocin (pitocin), pancreatic polypeptide, parathyroid hormone
(PTH), placental lactogen, prolactin (PRL), prolactin-release
inhibiting factor (PIF), prolactin-releasing factor (PRF),
secretin, somatostatin, somatotropin (growth hormone, GH),
somatostatin (SIF, growth hormone-release inhibiting factor, GIF),
thyrotropin (thyroid-stimulating hormone, TSH),
thyrotropin-releasing factor (TRH or TRF), thyroxine,
triiodothyronine, vasoactive intestinal peptide (VIP), and
vasopressin (antidiuretic hormone, ADH).
[0060] Particularly preferred analogues of LHRH include buserelin,
deslorelin, fertirelin, goserelin, histrelin, leuprolide
(leuprorelin), lutrelin, nafarelin, tryptorelin and combinations
thereof.
[0061] Kinins include bradykinin, potentiator B, bradykinin
potentiator C, and kallidin and combinations thereof.
[0062] Enzymes include transferases, hydrolases, isomerases,
proteases, ligases and oxidoreductases such as esterases,
phosphatases, glycosidases and peptidases. Specific examples of
enzymes include super oxide dismutase (SOD), tissue plasminogen
activator (TPA), renin, adenosine deaminase,
.beta.-glucocerebrosidase, asparaginase, domase-.alpha.,
hyaluronidase, elastase, trypsin, thymidin kinase (TK), tryptophan
hydroxylase, urokinase, and kallikrein. Enzyme inhibitors include
leupeptin, chymostatin, pepslatin, renin inhibitors, angiotensin
converting enzyme (ACE) inhibitors, and the like.
[0063] Antibodies include both monoclonal and polyclonal
antibodies, as well as antibody fragments, such as the
F(ab').sub.2, Fab, Fv and Fc fragments of monoclonal
antibodies.
[0064] Other peptidyl drugs: Still other peptidyl drugs that
provide a desired pharmacological activity can be incorporated into
the compositions and delivery systems of the invention. Examples
include abarelix, anakinra, ancestim, bivalirudin, bleomycin,
bombesin, desmopressin acetate, des-Q14-ghrelin, enterostatin,
erythropoeitin, exendin-4, filgrastim, gonadorelin, insulinotropin,
lepirudin, magainin I, magainin II, nerve growth factor,
pentigetide, thrombopoietin, thymosin .alpha.-1, and urotensin II
and combinations thereof.
[0065] The use of focused acoustic energy in the preparation of
peptide arrays substantially prevents exposure of the peptidic
molecules to high levels of shear stress. That is, acoustic
ejection techniques do not produce high shear forces within fluids
(in contrast to techniques that require a nozzle, for example) that
can degrade the structure of a peptidic molecule. Evidence of shear
stress includes any departure from the original or natural
three-dimensional structure of the peptidic molecule, e.g., loss of
protein folding. Substantially none--i.e., less than 10%,
preferably less than 5%, more preferably less than 1%, most
preferably less than 0.1%--of the peptidic molecules in an array
prepared using the present methodology exhibit signs of shear
stress.
[0066] In addition, the peptidic molecules in an array produced
using focused acoustic energy are intact and attached to a
predetermined site on the substrate surface. This is in contrast to
arrays prepared using photolithographic techniques, wherein
truncated forms of peptidic molecules (e.g., peptidic molecules
missing one or more amino acid residues) are often present.
Truncated peptidic molecules can result, for example, when a
photoprotecting group fails to detach during in situ synthesis.
Furthermore, inaccuracy in mask placement using a photolithographic
array preparation technique can result in attachment of individual
peptides to unintended sites on the substrate surface. Lastly,
photolithographic techniques are not amenable to the accurate
placement of pre-purified proteins but are primarily restricted to
in situ synthesis of small peptides with fewer than 25 amino acids.
None of these problems are encountered when focused acoustic energy
is used to prepare arrays.
[0067] The peptide arrays of the invention preferably include a
lipidic material attached to at least one designated site on the
substrate surface. The lipidic material may have been attached to
the designated site prior to deposition of the peptidic molecules,
or it may be associated with a particular peptidic molecule such
as, for example, a peptidic molecule within a phospholipid
envelope. In the latter case, the fluid containing the peptidic
molecule also includes the lipidic material. While many
array-forming techniques are incompatible with lipidic materials,
since lipidic compounds tend to be viscous, the present acoustic
ejection technique can effectively eject lipidic materials onto a
substrate along with the individual peptides.
[0068] Examples of suitable lipidic material include, but are not
limited to, the following: phospholipids such as phosphorylated
diacyl glycerides, and particularly phospholipids selected from the
group consisting of diacyl phosphatidylcholines, diacyl
phosphatidylethanolamin- es, diacyl phosphatidylserines, diacyl
phosphatidylinositols, diacyl phosphatidylglycerols, diacyl
phosphatidic acids, and mixtures thereof, wherein each acyl group
contains about 10 to about 22 carbon atoms and is saturated or
unsaturated; fatty acids such as isovaleric acid, valeric acid,
caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric
acid, lauric acid, myristic acid, palmitic acid, stearic acid,
arachidic acid, behenic acid, lignoceric acid, oleic acid, linoleic
acid, linolenic acid, and arachidonic acid; lower fatty acid esters
comprising esters of the foregoing fatty acids, wherein the
carboxylic acid group of the fatty acid is replaced with an ester
moiety --(CO)--OR wherein R is a C.sub.1-C.sub.3 alkyl moiety
optionally substituted with one or two hydroxyl groups; fatty
alcohols corresponding to the aforementioned fatty acids, wherein
the carboxylic acid group of the fatty acid is replaced by a
--CH.sub.2OH group; glycolipids such as cerebroside and
gangliosides; oils, including animal oils such as cod liver oil
and, menhaden oil, and vegetable oils such as babassu oil, castor
oil, corn oil, cotton seed oil, linseed oil, mustard oil, olive
oil, palm oil, palm kernel oil, peanut oil, poppyseed oil, rapeseed
oil, safflower oil, sesame oil, soybean oil, sunflower seed oil,
tung oil or wheat germ oil; and waxes, i.e., higher fatty acid
esters, including animal waxes such as beeswax and shellac, mineral
waxes such as montan, petroleum waxes such as microcrystalline wax
and paraffin, and vegetable waxes such as camauba wax.
[0069] The peptidic molecule may also be deposited in an aqueous
fluid. Aqueous fluids include water per se as well as aqueous
solutions, dispersions and suspensions of various nonfluidic
materials, and mixtures of water with other liquids.
[0070] The peptide array may be a homogenous peptide array (i.e.,
an array containing the same peptidic molecule) or a heterogeneous
peptide array (i.e., an array containing different peptidic
molecules). In a homogeneous peptide array, each peptidic molecule
is coupled in substantially the same orientation on a substrate.
Any technique for binding a peptidic molecule in substantially the
same orientation on a substrate may be employed. As will be
appreciated by those skilled in the art, the orientation of the
peptidic molecule using this approach is substantially preserved,
although rotation around chemical bonds is to be expected.
Nevertheless, the "exposed" portion of the peptide remains
substantially unchanged. In this way, the homogenous array displays
the same peptidic molecules in substantially the same orientation.
By way of a nonlimiting example, a monoclonal antibody is initially
bound to a specific epitope on a peptidic molecule. The peptidic
molecule-antibody complex is placed in a fluid and acoustically
ejected onto a desired location on a substrate surface covered with
antibody-binding protein. The peptidic molecule is in substantially
the same orientation since the antibody-binding protein binds to
only the Fc portion of the antibody in the antibody-peptidic
molecule complex. In another example, a peptidic molecule that has
only one exposed terminal carboxyl side chain is acoustically
ejected onto a substrate derivatized with an amine functionality
such that an amide linkage results. Because the single carboxyl
moiety of the peptide is coupled to the reactive amine on the
substrate surface, the peptidic compounds on the substrate surface
are in substantially uniform arrangement. Alternatively, a
substrate surface having monoclonal antibodies attached thereto can
bind the acoustically ejected peptidic molecules.
[0071] The use of such a focused acoustic ejection system enables
preparation of arrays that will generally have a density in the
range of approximately 10 to approximately 250,000 peptidic
molecules (generally 10 to approximately 250,000 different peptidic
molecules) per square centimeter of substrate surface, typically in
the range of approximately 400 to approximately 100,000 peptidic
molecules (again, generally 400 to approximately 1,000,000
different peptidic molecules) per square centimeter of substrate
surface.
[0072] However, it must be emphasized that the present method
enables preparation of far higher density arrays as well, i.e.,
arrays comprised of at least about 1,000,000 peptidic molecules per
square centimeter of substrate surface, or even in the range of
about 1,500,000 to 4,000,000 peptidic molecules per square
centimeter of substrate surface. These high density arrays may be
prepared on nonporous surfaces, although a significant advantage of
using focused acoustic energy technology in the manufacture of
combinatorial arrays is that substrates with porous surfaces, and
even permeable surfaces, may be used. Prior array fabrication
methods have not enabled preparation of high density arrays on
porous or permeable surfaces because prior spotting processes are
nowhere near as accurate as the present acoustic deposition method,
and prior processes have also required larger droplet volumes.
Accordingly, prior array fabrication methods have been limited to
the preparation of low density arrays on porous surfaces, or higher
density arrays on nonporous surfaces. See, for example, U.S. Pat.
No. 6,054,270 to Southern. In contrast to prior methods of
manufacturing arrays, then, the present acoustic ejection process
enables extraordinarily precise deposition of very small droplets,
as well as consistency in droplet size and velocity. Very high
array densities can now be achieved with high porosity, permeable
surfaces. More specifically, the present acoustic ejection method
can be used to manufacture high density arrays that can be read
with a high precision digitizing scanner capable of 2 .mu.m
resolution, by depositing droplets having a volume on the order of
1 pL, resulting in deposited spots about 18 .mu.m in diameter. For
ultra-high density arrays, a smaller droplet volume is necessary,
typically less than about 0.03 pL (deposition of droplets having a
volume on the order of 0.025 pL will result in deposited spots
about 4.5 .mu.m in diameter). Localization of deposited droplets
using chemical or physical means, such as described in the '270
patent, is unnecessary because acoustic ejection enables precisely
directed minute droplets to be deposited with accuracy at a
particular site.
[0073] Acoustic ejection devices are described in co-pending patent
application U.S. Ser. No. 09/669,996 ("Acoustic Ejection of Fluids
From a Plurality of Reservoirs"), inventors Ellson, Foote and Mutz,
filed Sep. 25, 2000 and assigned to Picoliter, Inc. (Mountain View,
Calif.). In addition, FIG. 1 illustrates, in simplified
cross-sectional view, a focused acoustic ejection device suitable
for ejecting fluids containing peptidic molecules. As with all
figures referenced herein, in which like parts are referenced by
like numerals, FIG. 1 is not to scale, and certain dimensions may
be exaggerated for clarity of presentation.
[0074] FIG. 1 illustrates an embodiment of the employed device in
simplified crosssectional view. As with all figures referenced
herein, in which like parts are referenced by like numerals, FIG. 1
is not to scale, and certain dimensions may be exaggerated for
clarity of presentation. The device 11 includes a plurality of
reservoirs, i.e., at least two reservoirs, with a first reservoir
indicated at 13 and a second reservoir indicated at 15, each
adapted to contain a fluid having a fluid surface, e.g., a first
fluid 14 and a second fluid 16 having fluid surfaces respectively
indicated at 17 and 19. Fluids 14 and 16 may be the same or
different, and may also have acoustic or fluidic properties that
are the same or different. As shown, the reservoirs are of
substantially identical construction so as to be substantially
acoustically indistinguishable, but identical construction is not a
requirement. The reservoirs are shown as separate removable
components but may, if desired, be fixed within a plate or other
substrate. For example, the plurality of reservoirs may comprise
individual wells in a well plate, optimally although not
necessarily arranged in an array. Each of the reservoirs 13 and 15
is preferably axially symmetric as shown, having vertical walls 21
and 23 extending upward from circular reservoir bases 25 and 27 and
terminating at openings 29 and 31, respectively, although other
reservoir shapes may be used. The material and thickness of each
reservoir base should be such that acoustic radiation may be
transmitted therethrough and into the fluid contained within the
reservoirs.
[0075] The device also includes an acoustic ejector 33 comprised of
an acoustic radiation generator 35 for generating acoustic
radiation and a focusing means 37 for focusing the acoustic
radiation at a focal point within the fluid from which a droplet is
to be ejected, near the fluid surface. As shown in FIG. 1, the
focusing means 37 may comprise a single solid piece having a
concave surface 39 for focusing acoustic radiation, but the
focusing means may be constructed in other ways as discussed below.
The acoustic ejector 33 is thus adapted to generate and focus
acoustic radiation so as to eject a droplet of fluid from each of
the fluid surfaces 17 and 19 when acoustically coupled to
reservoirs 13 and 15 and thus to fluids 14 and 16, respectively.
The acoustic radiation generator 35 and the focusing means 37 may
function as a single unit controlled by a single controller, or
they may be independently controlled, depending on the desired
performance of the device. Typically, single ejector designs are
preferred over multiple ejector designs because accuracy of droplet
placement and consistency in droplet size and velocity are more
easily achieved with a single ejector.
[0076] As will be appreciated by those skilled in the art, any of a
variety of focusing means may be employed in conjunction with the
present invention. For example, one or more curved surfaces may be
used to direct acoustic radiation to a focal point near a fluid
surface. One such technique is described in U.S. Pat. No. 4,308,547
to Lovelady et al. Focusing means with a curved surface have been
incorporated into the construction of commercially available
acoustic transducers such as those manufactured by Panametrics Inc.
(Waltham, Mass.). In addition, Fresnel lenses are known in the art
for directing acoustic energy at a predetermined focal distance
from an object plane. See, e.g., U.S. Pat. No. 5,041,849 to Quate
et al. Fresnel lenses may have a radial phase profile that
diffracts a substantial portion of acoustic energy into a
predetermined diffraction order at diffraction angles that vary
radially with respect to the lens. The diffraction angles should be
selected to focus the acoustic energy within the diffraction order
on a desired object plane.
[0077] There are also a number of ways to acoustically couple the
ejector 33 to each individual reservoir and thus to the fluid
therein. One such approach is through direct contact as is
described, for example, in U.S. Pat. No. 4,308,547 to Lovelady et
al., wherein a focusing means constructed from a hemispherical
crystal having segmented electrodes is submerged in a liquid to be
ejected. The aforementioned patent further discloses that the
focusing means may be positioned at or below the surface of the
liquid. However, this approach for acoustically coupling the
focusing means to a fluid is undesirable when the ejector is used
to eject different fluids in a plurality of containers or
reservoirs, as repeated cleaning of the focusing means would be
required in order to avoid cross-contamination. The cleaning
process would necessarily lengthen the transition time between each
droplet ejection event. In addition, in such a method, fluid would
adhere to the ejector as it is removed from each container, wasting
material that may be costly or rare.
[0078] Thus, a preferred approach would be to acoustically couple
the ejector to the reservoirs and reservoir fluids without
contacting any portion of the ejector, e.g., the focusing means,
with any of the fluids to be ejected. To this end, the present
invention provides an ejector positioning means for positioning the
ejector in controlled and repeatable acoustic coupling with each of
the fluids in the reservoirs to eject droplets therefrom without
submerging the ejector therein. This typically involves direct or
indirect contact between the ejector and the external surface of
each reservoir. When direct contact is used in order to
acoustically couple the ejector to each reservoir, it is preferred
that the direct contact is wholly conformal to ensure efficient
acoustic energy transfer. That is, the ejector and the reservoir
should have corresponding surfaces adapted for mating contact.
Thus, if acoustic coupling is achieved between the ejector and
reservoir through the focusing means, it is desirable for the
reservoir to have an outside surface that corresponds to the
surface profile of the focusing means. Without conformal contact,
efficiency and accuracy of acoustic energy transfer may be
compromised. In addition, since many focusing means have a curved
surface, the direct contact approach may necessitate the use of
reservoirs having a specially formed inverse surface.
[0079] Optimally, acoustic coupling is achieved between the ejector
and each of the reservoirs through indirect contact, as illustrated
in FIG. 1. In the figure, an acoustic coupling medium 41 is placed
between the ejector 33 and the base 25 of reservoir 13, with the
ejector and reservoir located at a predetermined distance from each
other. The acoustic coupling medium may be an acoustic coupling
fluid, preferably an acoustically homogeneous material in conformal
contact with both the acoustic focusing means 37 and each
reservoir. In addition, it is important to ensure that the fluid
medium is substantially free of material having different acoustic
properties than the fluid medium itself. As shown, the first
reservoir 13 is acoustically coupled to the acoustic focusing means
37 such that an acoustic wave is generated by the acoustic
radiation generator and directed by the focusing means 37 into the
acoustic coupling medium 41, which then transmits the acoustic
radiation into the reservoir 13.
[0080] In operation, each reservoir 13 and 15 of the device is
filled with a fluid containing a peptidic molecule, as explained
above. The acoustic ejector 33 is positioned by means of ejector
positioning means 43, shown below reservoir 13, in order to achieve
acoustic coupling between the ejector and the reservoir through
acoustic coupling medium 41. Substrate 45 is positioned above and
in proximity to the first reservoir 13 such that one surface of the
substrate, shown in FIG. 1 as underside surface 51, faces the
reservoir and is substantially parallel to the surface 17 of the
fluid 14 therein. Once the ejector, the reservoir and the substrate
are in proper alignment, the acoustic radiation generator 35 is
activated to produce acoustic radiation that is directed by the
focusing means 37 to a focal point 47 within fluid 14 near the
fluid surface 17. As a result, droplet 49 is ejected from the fluid
surface 17 onto a designated site on the underside surface 51 of
the substrate. The ejected droplet may be retained on the substrate
surface by solidifying thereon after contact; in such an
embodiment, it is necessary to maintain the substrate surface at a
low temperature, i.e., at a temperature that results in droplet
solidification after contact. Alternatively, or in addition, a
molecular moiety, e.g., a peptidic molecule, within the droplet
attaches to the substrate surface after contact, through, for
example, adsorption, physical immobilization, or covalent
binding.
[0081] Then, as shown in FIG. 2, a substrate positioning means 50
may be used to reposition the substrate 45 over reservoir 15 in
order to receive a droplet therefrom at a second designated site.
FIG. 2 also shows that the ejector 33 has been repositioned by the
ejector positioning means 43 below reservoir 15 and in acoustically
coupled relationship thereto by virtue of acoustic coupling medium
41. Once properly aligned as shown in FIG. 2, the acoustic
radiation generator 35 of ejector 33 is activated to produce
acoustic radiation that is then directed by focusing means 37 to a
focal point 48 within the reservoir fluids in reservoir 15, thereby
ejecting droplet 53 onto the substrate. It should be evident that
such operation is illustrative of how the inventive device may be
used to eject a plurality of fluids from reservoirs in order to
form a pattern, e.g., an array, on the substrate surface 51. It
should be similarly evident that the device may be adapted to eject
a plurality of droplets from one or more reservoirs onto the same
site of the substrate surface.
[0082] As discussed above, either individual, e.g., removable,
reservoirs or well plates may be used to contain fluids that are to
be ejected, wherein the reservoirs or the wells of the well plate
are preferably substantially acoustically indistinguishable from
one another. Also, unless it is intended that the ejector is to be
submerged in the fluid to be ejected, the reservoirs or well plates
must have acoustic transmission properties sufficient to allow
acoustic radiation from the ejector to be conveyed to the surfaces
of the fluids to be ejected. Typically, this involves providing
reservoir or well bases that are sufficiently thin to allow
acoustic radiation to travel therethrough without unacceptable
dissipation. In addition, the material used in the construction of
reservoirs must be compatible with the fluids contained therein.
Thus, if it is intended that the reservoirs or wells contain an
organic solvent such as acetonitrile, polymers that dissolve or
swell in acetonitrile would be unsuitable for use in forming the
reservoirs or well plates. For water-based fluids, a number of
materials are suitable for the construction of reservoirs and
include, but are not limited to, ceramics such as silicon oxide and
aluminum oxide, metals such as stainless steel and platinum, and
polymers such as polyester and polytetrafluoroethylene. Many well
plates suitable for use with the employed device are commercially
available and may contain, for example, 96, 384 or 1536 wells per
well plate. Manufactures of suitable well plates for use in the
employed device include Corning Inc. (Corning, N.Y.) and Greiner
America, Inc. (Lake Mary, Fla). However, the availability of such
commercially available well plates does not preclude manufacture
and use of custom-made well plates containing at least about 10,000
wells, or as many as 100,000 wells or more. For array forming
applications, it is expected that about 100,000 to about 4,000,000
reservoirs may be employed. In addition, to reduce the amount of
movement and time needed to align the ejector with each reservoir
or reservoir well, it is preferable that the center of each
reservoir is located not more than about 1 centimeter, preferably
not more than about 1 millimeter and optimally not more than about
0.5 millimeter from a neighboring reservoir center.
[0083] It will be appreciated that various components of the device
may require individual control or synchronization to form an array
on a substrate. For example, the ejector positioning means may be
adapted to eject droplets from each reservoir in a predetermined
sequence associated with an array to be prepared on a substrate
surface. Similarly, the substrate positioning means for positioning
the substrate surface with respect to the ejector may be adapted to
position the substrate surface to receive droplets in a pattern or
array thereon. Either or both positioning means, i.e., the ejector
positioning means and the substrate positioning means, may be
constructed from, for example, motors, levers, pulleys, gears, a
combination thereof, or other electromechanical or mechanical means
known to one of ordinary skill in the art. It is preferable to
ensure that there is a correspondence between the movement of the
substrate, the movement of the ejector and the activation of the
ejector to ensure proper array formation.
[0084] The device may also include certain performance-enhancing
features. For example, the device may include a cooling means for
lowering the temperature of the substrate surface to ensure, for
example, that the ejected droplets adhere to the substrate. The
cooling means may be adapted to maintain the substrate surface at a
temperature that allows fluid to partially or preferably
substantially solidify after the fluid comes into contact
therewith. The device may also include a means for maintaining
fluid in the reservoirs at a constant temperature, since repeated
application of acoustic energy to a fluid will result in heating,
which can in turn cause unwanted changes in fluid properties such
as viscosity, surface tension and density. Design and construction
of such temperature maintaining means are known to one of ordinary
skill in the art and will involve incorporation of at least one
heating element and/or at least one cooling element. Generally, it
is desired that a fluid containing a peptidic molecule be kept at a
constant temperature without deviating more than about 1.degree. C.
or 2.degree. C. therefrom. In addition, for fluids containing a
peptidic molecule that is particularly heat sensitive, it is
preferred that the fluid be kept at a temperature that does not
exceed about 10.degree. C. above the melting point of the fluid,
preferably at a temperature that does not exceed about 5.degree. C.
above the melting point of the fluid. Thus, for example, when the
fluid containing a peptidic molecule is aqueous, it may be optimal
to keep the fluid at about 4.degree. C. during ejection.
[0085] In some cases, a substrate surface may be modified prior to
formation of a peptide array thereon. Surface modification may
involve functionalization or defunctionalization, smoothing or
roughening, changing surface conductivity, coating, degradation,
passivation or otherwise altering the surface's chemical
composition or physical properties. A preferred surface
modification method involves altering the wetting properties of the
surface, for example to facilitate confinement of a droplet ejected
on the surface within a designated area or enhancement of the
kinetics for the surface attachment of molecular moieties contained
in the ejected droplet. A preferred method for altering the wetting
properties of the substrate surface involves deposition of droplets
of a suitable surface modification fluid at each designated site of
the substrate surface prior to acoustic ejection of fluids to form
an array thereon. In this way, the "spread" of the acoustically
ejected droplets may be optimized and consistency in spot size
(i.e., diameter, height and overall shape) ensured. One way to
implement the method involves acoustically coupling the ejector to
a modifier reservoir containing a surface modification fluid and
then activating the ejector, as described in detail above, to
produce and eject a droplet of surface modification fluid toward a
designated site on the substrate surface. The method is repeated as
desired to deposit surface modification fluid at additional
designated sites. This method is useful in a number of applications
including, but not limited to, spotting oligomers to form an array
on a substrate surface or synthesizing array oligomers in situ. As
noted above, other physical properties of the surface that may be
modified include thermal properties and electrical
conductivity.
[0086] The aforementioned focused acoustic energy system enables
ejection of droplets at a rate of at least about 1,000,000 droplets
per minute from the same reservoir, and at a rate of at least about
100,000 drops per minute from different reservoirs. In addition,
current positioning technology allows for the ejector positioning
means to move from one reservoir to another quickly and in a
controlled manner, thereby allowing fast and controlled ejection of
different fluids. That is, current commercially available
technology allows the ejector to be moved from one reservoir to
another, with repeatable and controlled acoustic coupling at each
reservoir, in less than about 0.1 second for high performance
positioning means and in less than about 1 second for ordinary
positioning means. A custom designed system will allow the ejector
to be moved from one reservoir to another with repeatable and
controlled acoustic coupling in less than about 0.001 second. In
order to provide a custom designed system, it is important to keep
in mind that there are two basic kinds of motion: pulse and
continuous. Pulse motion involves the discrete steps of moving an
ejector into position, emitting acoustic energy, and moving the
ejector to the next position; again, using a high performance
positioning means with such a method allows repeatable and
controlled acoustic coupling at each reservoir in less than 0.1
second. A continuous motion design, on the other hand, moves the
ejector and the reservoirs continuously, although not at the same
speed, and provides for ejection during movement. Since the pulse
width is very short, this type of process enables over 10 Hz
reservoir transitions, and even over 1000 Hz reservoir
transitions.
[0087] In order to ensure the accuracy of fluid ejection, it is
important to determine the location and the orientation of the
fluid surface from which a droplet is to be ejected with respect to
the ejector. Otherwise, ejected droplets may be improperly sized or
travel in an improper trajectory. Thus, another embodiment of the
invention relates to a method for determining the height of a fluid
surface in a reservoir between ejection events. The method involves
acoustically coupling a fluid-containing reservoir to an acoustic
radiation generator and activating the generator to produce a
detection acoustic wave that travels to the fluid surface and is
reflected thereby as a reflected acoustic wave. Parameters of the
reflected acoustic radiation are then analyzed in order to assess
the spatial relationship between the acoustic radiation generator
and the fluid surface. Such an analysis will involve the
determination of the distance between the acoustic radiation
generator and the fluid surface and/or the orientation of the fluid
surface in relationship to the acoustic radiation generator.
[0088] More particularly, the acoustic radiation generator may be
activated so as to generate low energy acoustic radiation that is
insufficiently energetic to eject a droplet from the fluid surface.
This is typically done by using an extremely short pulse (on the
order of tens of nanoseconds) relative to that normally required
for droplet ejection (on the order of microseconds). By determining
the time it takes for the acoustic radiation to be reflected by the
fluid surface back to the acoustic radiation generator and then
correlating that time with the speed of sound in the fluid, the
distance B and thus the fluid height--may be calculated. Of course,
care must be taken in order to ensure that acoustic radiation
reflected by the interface between the reservoir base and the fluid
is discounted. It will be appreciated by those of ordinary skill in
the art of acoustic microscopy that such a method employs
conventional or modified sonar techniques.
[0089] Once the analysis has been performed, an ejection acoustic
wave having a focal point near the fluid surface is generated in
order to eject at least one droplet of the fluid, wherein the
optimum intensity and directionality of the ejection acoustic wave
is determined using the aforementioned analysis optionally in
combination with additional data. The "optimum" intensity and
directionality are generally selected to produce droplets of
consistent size and velocity. For example, the desired intensity
and directionality of the ejection acoustic wave may be determined
by using not only the spatial relationship assessed as above, but
also geometric data associated with the reservoir, fluid property
data associated with the fluid to be ejected, and/or by using
historical droplet ejection data associated with the ejection
sequence. In addition, the data may show the need to reposition the
ejector so as to reposition the acoustic radiation generator with
respect to the fluid surface, in order to ensure that the focal
point of the ejection acoustic wave is near the fluid surface,
where desired. For example, if analysis reveals that the acoustic
radiation generator is positioned such that the ejection acoustic
wave cannot be focused near the fluid surface, the acoustic
radiation generator is repositioned using vertical, horizontal
and/or rotational movement to allow appropriate focusing of the
ejection acoustic wave.
[0090] In general, screening for the properties of the array
constituents will be performed in a manner appropriate to the
particular array. Screening for biological properties such as
ligand binding or hybridization may be generally performed in the
manner described in U.S. Pat. Nos. 5,744,305 and 5,445,934 to Fodor
et al. U.S. Pat. Nos. 5,143,854 and 5,405,783 to Pirrung et al.,
and U.S. Pat. Nos. 5,700,637 and 6,054,270 to Southern et al.
[0091] Screening for material properties may be effected by
measuring physical and chemical properties, including by way of
example rather than limitation, measuring the chemical, mechanical,
optical, thermal, electrical or electronic, by routine methods
easily adaptable to microarrays. In addition to bulk material
characteristics or properties, surface specific properties may be
measured by surface specific physical techniques and physical
techniques that are adapted to surface characterization.
Macroscopic surface phenomena including adsorption, catalysis,
surface reactions including oxidation, hardness, lubrication and
friction, may be examined on a molecular scale using such
characterization techniques. Various physical surface
characterization techniques include without limitation diffractive
techniques, spectroscopic techniques, microscopic surface imaging
techniques, surface ionization mass spectroscopic techniques,
thermal desorption techniques and ellipsometry. It should be
appreciated that these classifications are arbitrary made for
purposes of explication, and some overlap may exist.
[0092] Peptide arrays, as prepared using the present method, have a
variety of applications. For example, homogeneous protein
arrays--i.e., arrays having proteins oriented in substantially the
same orientation--allow for the facile quantitation of antibody
titer by determining the number of antibodies that bind to the
array from a known sample volume. Alternatively, the relative
affinities of ligands to a peptidic molecule may be readily
established by identifying the number of peptide-bound ligands and
comparing the number for each ligand tested. Homogeneous peptide
arrays in which the peptidic molecules are in different
orientations are useful, for example, in high throughput screening
applications wherein a large number of potential ligands are passed
over the array. Those that bind to the peptide array can be
separated and further evaluated, via size-exclusion chromatography,
mass spectrometry, or the like. Heterogeneous peptide arrays are
useful for screening a particular ligand against a large number of
peptidic molecules. The ligand is allowed to come into contact with
the peptide array and unbound ligand is washed away. The array is
read to identify signals indicating that the ligand has affinity
for a particular peptide. That is, by labeling potential ligands,
e.g., with a fluorescent label, in a library of compounds,
contacting the library with the peptide array under binding
conditions, allowing binding (if any) to occur, and subsequently
washing unbound compounds, it is possible to detect whether any
compound in the library binds to the biological receptor by
detecting the fluorescent signal, for example with a confocal
detection apparatus. In this way, it is possible to determine which
receptor is bound by determining the "address" of the signal that
correlates to the specific biological receptor placed at that
address during array manufacture. The bound ligand can then be
separated, such as by treating the array with a strong acid, and
collected for further study. The method thus enables one to screen
a large number of potential ligands that can act as antagonists or
agonists for a particular biological receptor. Once identified,
ligands can serve as probes or be formulated into pharmaceutical
preparations. Another application is the use of homogeneous arrays
composed of many replicates of two proteins that have a measurable
binding affinity. A plurality of molecules may then be added to the
array to see if these molecules enhance or disrupt protein-protein
binding.
[0093] It is to be understood that while the invention has been
described in conjunction with the preferred specific embodiments
thereof, the foregoing description is intended to illustrate and
not limit the scope of the invention. Other aspects, advantages and
modifications will be apparent to those skilled in the art to which
the invention pertains.
[0094] All patents, patent applications, journal articles and other
references cited herein are incorporated by reference in their
entireties.
[0095] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to implement the invention, and are not intended
to limit the scope of what the inventors regard as their invention.
Efforts have been made to ensure accuracy with respect to numbers
(e.g., amounts, temperature, etc.) but some errors and deviations
should be accounted for. Unless indicated otherwise, parts are
parts by weight, temperature is in .degree. C. and pressure is at
or near atmospheric.
EXAMPLE 1
[0096] This example demonstrates that deposition of a peptidic
molecule on a substrate using focused acoustic energy does not
affect the structure or activity of the molecule. The peptidic
molecule employed was TAQ polymerase, a thermostable DNA
polymerase. TAQ Polymerase Master Mix from Qiagen was used as the
source for TAQ polymerase.
[0097] The polymerase was ejected using a focused acoustic energy
system from a well plate onto a polypropylene receiving tube using
an F=2 lens. The enzymatic activity of the deposited polymerase was
then evaluated using a polymerase chain reaction (PCR) assay. For
this experiment, TAQ was used to amplify a randomly chosen sequence
of the Puc18 vector (Amersham). The following primers were
used:
[0098] Forward 5'AACGTTGTAAAACGACGGCCAGT (SEQ ID NO.: 1); and
[0099] Reverse 5'ACGATAGTTACCGGATAAGGCGC (SEQ ID NO.: 2) at final
concentrations of 1.0 .mu.M each.
[0100] The composition of the reaction mixture was 1 .mu.g Puc18
DNA, 25 .mu.L master mix, 22 .mu.L H.sub.2O and 1 .mu.L of each
primer at a starting concentration of 50 .mu.M. The cycling
reaction was performed as follows: 4 minutes at 96.degree. C.; and
then 30 cycles of 45 seconds at 96.degree. C., 45 seconds at
52.degree. C., and 45 seconds at 72.degree. C. This was followed by
a 10 minute extension reaction at 72.degree. C. The extent of the
PCR reaction was evaluated by agarose gel electrophoresis. stained
with ethidium bromide at a concentration of 0.5 .mu.g/ml. The
thermocycling reaction was performed on an instrument manufactured
by MWG Biotech, Ebersberg, Germany.
[0101] The intensity of the 1 kb DNA product band for TAQ
transferred via focused acoustic ejection was similar to that of
the band intensity for non-ejected TAQ. Therefore, it appears that
this protein may be subjected to focused acoustic ejection without
significant loss of enzymatic activity.
[0102] Because some of the reagents used in peptide deposition
and/or synthesis are moisture-sensitive, deposition and/or coupling
must be performed under anhydrous conditions in a sealed chamber or
container. This may be accomplished by performing the acoustic
spotting in a chamber of desiccated gas obtained by evacuating a
chamber that contains the acoustic ejection device and synthetic
substrate and replacing the evacuated atmospheric gas with
desiccated N.sub.2 by routine methods; washing steps may be
performed in the chamber or by removing the slide and washing it in
an appropriate environment, for example, by a staining jar fitted
with a drying tube. Because washing and other steps such as
detritylation may be more conveniently carried out outside the
chamber, the synthesis may also be performed in a controlled
humidity room that contains the controlled atmosphere chamber in
which the spotting is done, with the other steps carried out in the
room outside the chamber. Alternatively, a controlled humidity room
may be used for spotting with other steps carried out in less
controlled environment by use of, for example, a staining jar
fitted with a drying tube.
EXAMPLE 2
[0103] This example describes preparation of a peptide array in the
form of a combinatorial library, and demonstrates the use of
focused acoustic energy in the combinatorial solid phase synthesis
of all tetramers that can be made from the 20 naturally occurring
amino acids (20.sup.4 or=160,000 amino acid sequences in all) in a
quadruplicate array format. Four identical copies of the
combinatorial array to be prepared are contained in a 1 cm=1 cm
area nominally divided into four quadrants, each quadrant
containing 250,000 synthesized sites of size 10 .mu.m=10 .mu.m
arrayed in 500 rows and 500 columns. Only 400 rows and columns are
used in each quadrant; the first and last 50 rows and columns are
not used for synthesis, and function to space the four identical
arrays from each other and the edges of the area, although
alternative arrangement of the four identical arrays can obtain
greater distance between arrays by moving each array closer to the
corners of the square area. In addition to systematically
generating the combinatorial sequences, deposition of the monomers
employs a systematic method of ensuring that similar amino acid
sequences are less likely to be adjacent or near to each other.
Although many such methods exist, with some requiring sophisticated
computation, the scheme used relies on a basic sequential list of
amino acids that is phase shifted as the row number increases. The
20 natural amino acids can be listed sequentially based on the
alphabetic order of their single letter abbreviations, in which
case: Ala (A) is "1"; Cys (C) is "2"; Asp (D) is 3; . . . Val (V)
is "19"; and Trp (W) is "20".
[0104] For the first monomer deposited, in the first row in a given
quadrant in which a peptide is synthesized, which is the 51.sup.st
nominal row in that quadrant, beginning with the first synthetic
column (51.sup.st nominal column) amino acids (as activated for the
synthesis described in more detail below) are deposited as the
basic sequential list from 1 to 20 in alphabetical order of the one
letter abbreviations. Beginning with the second synthetic row
(52.sup.nd nominal row), the order is shifted by one position
starting at "2" and returning to "1" after "20" (2, 3, 4, 5 . . .
19, 20, 1); thus for the quadruplicate spaced array arrangement
being made, in the 52.sup.nd nominal row (second synthetic row) of
a given quadrant, the first amino acid deposited in the 51.sup.st
and 431.sup.st nominal column of the 52.sup.nd nominal row is "2"
or Cys, and the amino acids deposited in the 68.sup.th and
448.sup.th, 69.sup.th and 449.sup.th, and 70.sup.th and 450.sup.th
nominal columns of this row are 19, 20 and 1 respectively (V, W,
A).
[0105] Additional monomers are added in the quadrants as follows,
although numerous alternatives exist. For the second monomer in the
first synthetic row (51.sup.st nominal row) the monomer deposition
order for the second monomer is the same as for the first monomer
in the first 20 synthetic columns (nominal 51-70) of this row, and
the order is shifted by one for each successive group of 20
synthetic columns, thus the order is 2, 3 . . . 19, 20, 1 for
nominal columns 71-90 (hereinafter denoted [71-90 ]--{2, 3 . . .
19, 20, 1}) and according to this notation: [91-110]--{3, 4 . . .
20, 1, 2}; [111-130]--{4, 5 . . . 1, 2, 3} . . . [431-450]--{20, 1
. . . 17, 18, 19}. For the second and third monomers in the second
synthetic row (52.sup.nd nominal row) the monomer deposition order
is shifted by one relative to the order for the underlying monomer
in the first 20 synthetic columns (nominal 51-70) of this row, and
the order is shifted by one for each successive group of 20
synthetic columns, thus for the second monomer the order is 3, 4 .
. . 20, 1, 2 for nominal columns 51-70 and: [71-90]--{4, 5 . . . 1,
2, 3} [91-110]--{5, 6 . . . 2, 3, 4}; [111-130]--6, 7 . . . 3, 4,
5} . . . [431-450]--{2, 3 . . . 19, 20, 1}. Note that for the
second monomer of the second synthetic row, the shift relative to
the order of the first monomer in the first monomer in the first 20
columns of the first row ({1, 2 . . . 18, 19, 20}), is 2 because
one is the shift between subsequent monomers (1.sup.st2.sup.nd,
2.sup.nd3.sup.rd) and the first monomer of the second synthetic row
is shifted by one relative to the first monomer of the first
synthetic row. For the second and third monomers in the third
synthetic row (53.sup.rd nominal row) the monomer deposition order
is shifted by two relative to the order for the underlying monomer
in the first 20 synthetic columns (nominal 51-70) of this row, and
the order is shifted by one for each successive group of 20
synthetic columns, thus the order for the second monomer is 5 . . .
20, 1, 2, 3, 4 for nominal columns 51-70 and: [71-90]--{6 . . . 1,
2, 3, 4, 5},[91-110]--{7, . . . 2, 3, 4, 5, 6},[111-130]--{8, . . .
4, 5, 6, 6, 7} . . . [431-450]--{4, . . . 19, 20, 1, 2, 3}. For the
second monomer in the Nth synthetic row (nominal row=50 +N) the
monomer deposition order for the second monomer is shifted by (N-1)
relative to the order for the first monomer in the first 20
synthetic columns (nominal 51-70) of this row, and the order is
shifted by one for each successive group of 20 synthetic columns,
thus (for (k*N+a)>20,(k*N+a) is shifted as beginning with
N+a-20*1, where I is the integer dividend of the quotient of
(k*N+a) and 20, representing number of cycles with each integral
multiple of 20 representing unshifted) the order for the second
monomer is (2*N-1), 2*N . . . (2*N-3), (2*N-2) for nominal columns
51-70 and: [71-90]--{(2*N . . . (2*N-2), (2*N-1)},
[91-110]--{(2*N+1), (2*N+2) . . . (2*N-1), 2*N},
[111-130]--{(2*N+2), (2*N+3) . . . 2*N, (2*N+1)} . . .
[431-450]--{(2*N-2), (2*N-1) . . . (2*N-4), (2*N-3)}. Thus for the
second monomer in the 400h synthetic row (450.sup.th nominal row)
the monomer deposition order for the second monomer begins with 19
(799-780) is circularly shifted by 18 relative to the order for the
first monomer in the first 20 synthetic columns (nominal 51-70) of
the first row, and the order is shifted by one for each successive
group of 20 synthetic columns, thus the order is 19, 20 . . . (17),
(18) for nominal columns 51-70 and: [71-90]--{20, 1 . . . 17, 18,
19}, [91-110]--{1, 2 . . . 18, 19, 20}, [111-130]--{2, 3 . . . 19,
20, 1} . . . [431-450]--{20, 1 . . . 17, 18, 19}. Note that for the
second monomer of the Nth synthetic row, the shift relative to the
order of the first monomer in the in the first 20 synthetic columns
of the first row ({1, 2 . . . 18, 19, 20}), is 2*(N-1 ) because
(N-1) is the shift between subsequent monomers (1.sup.st 2.sup.nd ;
2.sup.nd 3 .sup.rd) and the first monomer of a synthetic row N is
shifted by (N-1 ) relative to the first monomer of the first
synthetic row.
[0106] The synthetic chemical steps are modified from known solid
phase synthetic techniques (as described, for example, in Geysen et
al., International Patent Application PCT/AU84/00039, now WO
84/83564) that are adapted from the pioneering solid phase peptide
synthesis of Merrifield et al. ((1965) Nature 207:(996):522-23;
(1965) Science 150(693)178-85; (1966) Anal. Chem. 38(13):1905-14;
(1967) Recent. Prog. Horm. Res. 23:451-82). The conventional
methods of solid phase peptide synthesis as taught in these seminal
papers are described in detail in Ericksen, B. W. and Merrifield,
R. B. (1973) The Proteins 2:255-57 Academic Press, New York, and
Meinhofer, J. (1976) The Proteins 2:45-267 Academic Press, New
York. Briefly, all these methods add amino acid monomers protected
by tert-butoxycarbonyl (t-butoxycarbonyl, t-Boc) at their amino
groups, including their alpha amino groups (N.sup..alpha.) to a
nascent peptide that is attached to the substrate at the
carboxy-terminal (C-terminal). The carbonyl moiety of the
N.sup..alpha.-t-Boc amino acid to be added to the peptide is
activated to convert the hydroxyl group of the carboxylic moiety
into an effective leaving group, resembling an acid anhydride in
reactivity, using dicyclohexylcarbodiimide (DCC) to permit
nucleophilic displacement by the terminal N of the nascent peptide
to form a peptide bond that adds the monomer to the forming
peptide. The newly added monomer has an N-terminus protected from
further reaction by t-Boc, which is removed with trifluoroacetic
acid (TFA), rendering the terminal amino group protonated, followed
by deprotonation of the terminal amino group with triethylamine
(TEA) to yield the reactive free amino group suitable for addition
of another monomer.
[0107] The substrate employed is polyethylene, although the classic
substrate for solid phase peptide synthesis, divinylbenzene
cross-linked polystyrene chloromethylated by Friedel-Crafts
reaction of the polystyrene resin on approximately one in four
aromatic rings, could also be employed. Preparation of the
polyethylene substrate, described in Geysen et al., International
Patent Application PCT/AU84/00039, published as WO 84/83564,
involves .gamma.-ray irradiation (1 mrad dose) of polyethylene
immersed in aqueous acrylic acid (6% v/v) to yield reactive
polyethylene polyacrylic acid (PPA), according to the method of
Muller-Schulte et al. (1982) Polymer Bulletin 7:77-81.
N.sup..alpha.-t-Boc-Lysine methyl ester is then coupled to the PPA
by the Lysine .epsilon.-amino side chain. After deprotection of the
N.sup..alpha. by removal of the t-Boc with TFA followed by TEA,
DCC/N.sup..alpha.-t-Boc-Alanine is added to couple t-Boc-Ala to the
N.sup..alpha. of the Lys, thereby forming a peptide like
N.sup..alpha.-t-Boc-Ala-Lys-.epsilon.-N-PPA linker to which the DCC
activated N.sup..alpha.-t-Boc-amino acid monomers can be
sequentially added to form the desired polymers upon deprotection
of the N.sup..alpha. group of the N.sup..alpha.-t-Boc-Ala.
[0108] The polyethylene substrate can be commercially available
smooth polyethylene sheet material, of various thicknesses.
Polyethylene beads may be adhered to a surface in a manner that
allows them to be separated from the surface by use of low
molecular weight polyethylene as an adhesive. Appropriately sized
polyethylene beads, activated, for example, by .gamma.-irradiation
in the presence of acrylic acid to form PPA, may be applied to a
smooth polyethylene surface or a glass, or other surface coated
with low molecular weight polyethylene, or the adhesion step can be
performed prior to activation.
[0109] For an array format, and to increase the effective surface
area for polymer formation and enhance adhesion of acoustically
ejected reagent droplets to the synthetic substrate, polyethylene
fiber sheet material, approximate thickness 25 .mu.m, is heat or
fusion bonded to a smooth polyethylene backing approximately 0.15
cm thick to form a polyethylene fiber coated rough permeable
substrate. The fiber-coated sheet is cut into strips having the
approximate dimensions of a commercial slide, and
.gamma.-irradiated (1 mrad) in 6% v/v aqueous acrylic acid to form
the PPA activated substrate. The substrate must be adequately dried
because the t-Boc-protected and DCC-activated reagents are water
sensitive, and the water contained in acidic reagents such as TFA
can hydrolyze peptide bonds. Thus, anhydrous synthetic conditions
are required throughout. Conventional drying of the substrate is
effected with warm dry air at atmospheric or subatmospheric
pressure by routine methods; specifically, the slides are washed
with MeOH, Et.sub.2O, then air dried and stored in desiccated form
at -20.degree. C. until use.
[0110] The sequential combinatorial addition of monomers is
performed with all sites spotted with the appropriate
DCC/N.sup..alpha.-t-Boc-amino acid. The basic quasi-parallel
combinatorial synthesis of all tetramers that can be made from the
naturally occurring amino acids may be performed in 44 steps
excluding substrate preparation. As no selective linker
deprotection is required, the substrate is immersed in TFA in a
staining jar fitted with a drying tube, then washed, and immersed
in TEA, and washed again, all under anhydrous conditions. The
synthesis must be carried so that ejection of the fluid droplets
occurs in a controlled atmosphere, which is dry and inert to the
reagents used. This may be done by performing acoustic spotting in
a chamber of desiccated gas obtained by evacuating a chamber that
contains the acoustic ejection device and synthetic substrate and
then replacing the evacuated atmospheric gas with desiccated
N.sub.2; washing steps may be performed in the chamber or by
removing the slide and washing it in an appropriate environment,
for example, by a staining jar fitted with a drying tube. Because
washing and other steps such as detritylation may be more
conveniently carried out outside the chamber, the synthesis may
also be performed in a controlled humidity room that contains the
controlled atmosphere chamber in which the spotting is done, with
the other steps carried out in the room outside the chamber.
Alternatively, a controlled humidity room may be used for spotting,
with other steps carried out in less controlled environment by use
of, for example, a staining jar fitted with a drying tube.
[0111] Use of pre-synthesized short oligopeptides can also be used
in lieu of amino acid monomers. Since focused acoustic ejection
enables the rapid transition from the ejection of one fluid to
another, many oligopeptides can be provided in small volumes on a
single substrate (such as a microtiter plate) to enable faster
assembly of amino acid chains. For example, all possible peptide
dimers may be synthesized and stored in a well plate of over 400
wells. Construction of the tetramers can than be accomplished by
deposition of only two dimers per site and a single linking step.
Extending this further, a well plate with at least 8000 wells can
be used to construct peptides with trimers.
EXAMPLE 3
[0112] This example demonstrates the use of focused acoustic
ejection technology in generating peptidic arrays. Acoustic
ejection of antibiotin polyclonal antibody (obtained from Sigma, St
Louis, Mo.), green fluorescent protein (GFP) (obtained from Roche
Biochemicals, Palo ALto, Calif.), anti-GFP monoclonal antibody
(obtained from Roche Biochemicals, Palo Alto, Calif.), and lysozyme
(obtained from Sigma, St Louis, Mo.), was carried out using an F=3
lens with a 6 mm aperture and a nominal 18 mm focal length in the
reservoir fluid (40% glycerol, 60% phosphate buffered saline [PBS],
pH=7.5).
[0113] Peptidic solutions were prepared in the aforementioned
reservoir fluid with the peptidic molecules-antibiotin, GFP,
anti-GFP and lysozyme--at a concentration of 100 .mu.g/mL for
anti-GFP, GFP and lysozyme (as a negative control). The solutions
were printed onto aldehyde-coated slides obtained from NOAB
Diagnostics (Mississauga, Ontario, Canada) and epoxy-coated slides
obtained from Eppendorf AG (Hamburg, Germany). Droplet size was 60
picoliters and produced 120 .mu.m spots. The spots were placed 500
.mu.m apart. The printed arrays were then incubated for 15 hours at
room temperature in a humid chamber, followed by washing in
PBS-lysozyme (1% weight/volume) for one minute, and finally by a
1.times.PBS wash. Labels--(1) 100 .mu.g/mL Biotin, and (2) 0.5
.mu.g/mL GFP)--were diluted into a PBS solution containing 0.1%
Tween-20 (v/v) and 1% lysozyme (PBS-T-L), and the printed arrays
were incubated with the label solution for 90 minutes at room
temperature. The slides were washed in 1.times.PBS and 100 .mu.g/ml
Cy3-streptavidin was added in PBS-T-L buffer. After 30 minutes
further incubation at room temperature, the arrays were rinsed once
with PBS, then 3 times with PBS containing 0.1% Tween-20 (v/v) for
3 minutes, followed by two rinses with PBS. The rinsed arrays were
dried with a stream of nitrogen gas, and scanned on an Axon 4000B
(Union City, Calif.) scanner.
[0114] All peptidic materials were found to maintain activity after
arraying as confirmed by the presence of binding activity for the
antibodies, and by fluorescence, in the case of GFP. GFP and the
fluorescently labeled antibodies exhibited higher signal than
unlabeled lysozyme, used here as a negative control.
* * * * *